Immunic announces positive outcome of interim analysis of phase 3 ensure program of vidofludimus calcium in relapsing multiple sclerosis

– based on a review of unblinded data, an independent data monitoring committee (idmc) confirmed that predetermined futility criteria have not been met – – idmc also recommended continuing trial without changes, including no need for a potential upsizing – – ensure program remains on track to be completed in 2026 – – webcast to be held today, october 22, at 8:00 am et – new york , oct. 22, 2024 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ensure program, investigating lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), for the treatment of relapsing multiple sclerosis (rms). based on the outcome of the interim futility analysis, an unblinded independent data monitoring committee (idmc) has recommended that the trials are not futile and should continue as planned.
IMUX Ratings Summary
IMUX Quant Ranking